Pfizer cans Lipitor ads, vowing 'clarity'

Share this article:

Pfizer pulled Lipitor ads featuring Dr. Robert Jarvik and vowed that it is “committing to ensuring greater clarity in the roles and responsibilities of its spokespeople in its consumer advertising and promotion.”

In a Feb. 25 statement, Pfizer's Ian Read, president of worldwide pharmaceutical operations, defended Jarvik, the campaign and DTC but said: “Nevertheless, the way in which we presented Dr. Jarvik in these ads has, unfortunately, led to misimpressions and distractions from our primary goal of encouraging patient and physician dialogue on the leading cause of death in the world—cardiovascular disease.”

“Going forward, we commit to ensuring there is greater clarity in our advertising regarding the presentation of spokespeople,” Read said, adding that future campaigns, “to be launched in several weeks,” will continue to stress the importance of patients talking to their doctors.

Kaplan Thaler Group handles consumer advertising on the brand. For the first three quarters of 2007, Pfizer spent $118 million on Lipitor DTC ads, according to TNS Media Intelligence.

The ads became the target of a congressional investigation in January. The resulting news coverage, including the revelations that Jarvik was promised $1.35 million for his participation in the campaign and that a stunt double portrayed him rowing across a lake, was embarrassing for Pfizer. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?